CTRI/2012/08/002850已完成3 期
Evaluation of hepatoprotective effect of Picroliv in patients receiving multi drug therapy for Tuberculosis.
CSIR Central Drug research Institute0 个研究点目标入组 260 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1 Patients over the age of 16 years.
- •2 Willing to give informed consent and comply with protocol requirements and follow up.
- •3 Diagnosed as Category I, II or III tuberculosis of the RNTCP (Revised National Tuberculosis Control Program).
- •4 Receiving treatment with at least 3 anti tubercular drugs or as per the RNTCP guidelines.
排除标准
- •1 Unwilling to comply with protocol requirements and duration of follow up.
- •2 History of jaundice in the past 6 months.
- •3 History of having received any drug from the non allopathic systems of medicine in the past 3 months.
- •4 Pregnancy.
- •5 Severe hepatic, renal or cardiac disease.
- •6 H/o consuming alcohol daily.
研究者
相似试验
尚未招募
3 期
Assessing the effect of Bilwadi Agada to protect the liver from alcohol damage A Clinical studyCTRI/2024/07/070631Sanjeevini Ayurveda Medical College and Hospital
尚未招募
2 期
RoleofAyurvedic Medicine In Liver Cancer.CTRI/2022/06/043136ational Institute of Ayurveda Jaipur
招募中
3 期
Evaluation of the effect of oral prolive on liver function in patients with major and intermediate thalassemiaIRCT20191010045050N1Arak University of Medical Sciences40
招募中
不适用
Study of Hepatoprotective activity of PTK as an add on therapy in the patients of Tuberculosis on ATT - A Double blind Randomized control clinical studyCTRI/2021/11/037978Central Council for Research in Ayurvedic Sciences
招募中
4 期
use of Aloevera in liver diseaseCTRI/2011/12/002284A100